<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dosing of combination inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) when used for COPD</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dosing of combination inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) when used for COPD</h1>
<div class="graphic"><div class="figure"><div class="ttl">Dosing of combination inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) when used for COPD</div><div class="cntnt"><table cellspacing="0"><colgroup width="50%"></colgroup><colgroup span="2" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Name</td> <td class="subtitle1">Dose (adults)</td> <td class="subtitle1">Maximum dose</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Available in the United States</td> </tr> <tr> <td class="indent1">Budesonide-formoterol MDI<br/> (brand name [United States]: Symbicort, Breyna)<sup>¶</sup></td> <td>2 inhalations twice daily<br/> (160/4.5 mcg/actuation)</td> <td>2 inhalations twice daily</td> </tr> <tr> <td class="indent1">Fluticasone propionate-salmeterol MDI<br/> (brand names [United States]: Advair HFA)*<sup>¶</sup><sup>Δ</sup></td> <td>2 inhalations twice daily<br/> (115/21 mcg/actuation)</td> <td>2 inhalations twice daily</td> </tr> <tr> <td class="indent1">Fluticasone propionate-salmeterol DPI<br/> (brand names [United States]: Advair Diskus, Wixela Inhub)<sup>¶</sup><sup>◊</sup></td> <td>1 inhalation twice daily<br/> (250/50 mcg/actuation)<br/> (500/50 mcg/actuation)<sup>Δ</sup><sup>§</sup></td> <td>1 inhalation twice daily</td> </tr> <tr> <td class="indent1">Fluticasone furoate-vilanterol DPI<br/> (brand name [United States]: Breo Ellipta)<sup>◊</sup><sup>¥</sup></td> <td>1 inhalation once daily<br/> (100/25 mcg/actuation)</td> <td>1 inhalation once daily</td> </tr> <tr> <td class="indent1">Mometasone-formoterol MDI<br/> (brand name [United States]: Dulera)<sup>Δ</sup></td> <td>2 inhalations twice daily<br/> (100/5 mcg/actuation)<br/> (200/5 mcg/actuation)<sup>§</sup></td> <td>2 inhalations twice daily</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Not available in the United States but are widely available elsewhere</td> </tr> <tr> <td class="indent1">Beclometasone-formoterol MDI and DPI<br/> (brand name [UK and Europe]: Fostair [MDI] and Fostair Nexthaler [DPI])</td> <td>2 inhalations twice daily<br/> (100/6 mcg/actuation)</td> <td>2 inhalations twice daily</td> </tr> <tr> <td class="indent1">Budesonide-formoterol DPI<br/> (brand name [Canada]: Symbicort 200 Turbuhaler)<sup>◊</sup></td> <td>2 inhalations twice daily<br/> (200/6 mcg/actuation)</td> <td>2 inhalations twice daily</td> </tr> <tr> <td class="indent1">Budesonide-formoterol DPI<br/> (brand name [Canada]: Symbicort Forte Turbuhaler)<sup>◊</sup></td> <td>1 inhalation twice daily<br/> (400/12 mcg/actuation)</td> <td>1 inhalation twice daily</td> </tr> <tr> <td class="indent1">Fluticasone propionate-salmeterol MDI<br/> (brand name [Canada]: Advair)<sup>¶</sup><sup>Δ</sup></td> <td>2 inhalations twice daily<br/> (Canada: 125/25 mcg/actuation)</td> <td>2 inhalations twice daily</td> </tr> <tr> <td class="indent1">Fluticasone propionate-salmeterol DPI<br/> (brand names [Canada]: Advair Diskus, Wixela Inhub)<sup>¶</sup><sup>◊</sup></td> <td>1 inhalation twice daily<br/> (250/50 mcg/actuation)<br/> (500/50 mcg/actuation)<sup>§</sup></td> <td>1 inhalation twice daily</td> </tr> <tr> <td class="indent1">Fluticasone furoate-vilanterol DPI<br/> (brand name [Canada]: Breo Ellipta)<sup>◊</sup><sup>¥</sup></td> <td>1 inhalation once daily<br/> (100/25 mcg/actuation)</td> <td>1 inhalation once daily</td> </tr> <tr> <td class="indent1">Mometasone-formoterol MDI<br/> (brand name [Canada]: Zenhale)<sup>Δ</sup></td> <td>2 inhalations twice daily<br/> (100/5 mcg/actuation)<br/> (200/5 mcg/actuation)<sup>§</sup></td> <td>2 inhalations twice daily</td> </tr> </tbody></table></div><div class="graphic_lgnd">Recommended doses and strengths (ie, mcg/actuation) are for products within country or area listed; strengths and doses may be different for similar ingredient products available elsewhere. Consult local product information before use.</div><div class="graphic_footnotes"><p>MDI: metered dose inhaler; HFA: metered dose inhaler with hydrofluoroalkane propellant; DPI: dry powder inhaler; ICS: inhaled corticosteroid; LABA: long-acting beta-agonist.</p>
<p>* Fluticasone propionate-salmeterol (AirDuo RespiClick) contains a lower dose of salmeterol per inhalation and is used in asthma, but not COPD.</p>
<p>¶ Generic equivalent may be available in United States, Canada, and some other countries.</p>
<p>Δ ICS-LABA agent off-label for COPD.</p>
<p>◊ DPIs contain lactose and may contain small amounts of milk protein.</p>
<p>§ Additional benefit from this higher ICS dose relative to standard dose is uncertain; risk of pneumonia and systemic adverse effects may be increased.</p>
¥ Fluticasone furoate has a greater anti-inflammatory potency per microgram than fluticasone propionate inhalers. Thus, fluticasone furoate is administered at a lower daily dose and used only <strong>once</strong> daily.</div><div class="graphic_reference">Approved product labeling with additional information from Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2023 Report. Global Initiative for Chronic Obstructive Lung Disease website. <a href="https://goldcopd.org/wp-content/uploads/2022/12/GOLD-2023-ver-1.1-2Dec2022_WMV.pdf" target="_blank">https://goldcopd.org/wp-content/uploads/2022/12/GOLD-2023-ver-1.1-2Dec2022_WMV.pdf</a>.</div><div id="graphicVersion">Graphic 122859 Version 9.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
